

## PATENT COOPERATION TREATY

ECD 22 JUN 2004

PCT

WIPO/524198 PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

(Rationalised Report according to the Notice of the President of the EPO published in the OJ11/2001)


Applicant's or agent's file reference  2002.013 WO	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No.  PCT/EP03/08704	International filing date (day/month/year)  06/08/2003	Priority date (day/month/year)  12/08/2002
International Patent Classification (IPC) or national classification and IPC  C12N15/31		
Applicant  AKZO NOBEL N.V. et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 2 sheets, including this cover sheet.
 

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consists of a total of \_\_\_\_\_ sheets.
3. This report contains indications relating to the following items:
  - I  Basis of the report
  - II  Priority
  - III  Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
  - IV  Lack of unity of invention
  - V  Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
  - VI  Certain documents cited
  - VII  Certain defects in the international application
  - VIII  Certain observations on the international application

Date of submission of the demand  08/03/2004	Date of completion of this report  16/06/2004
Name and mailing address of the IPEA/  European Patent Office D-80298 Munich Tel. (+49-89) 2399-0, Tx: 523656 epmu d Fax: (+49-89) 2399-4465	Authorized officer  GUGERELL C  Tel. (+49-89) 2399 2828



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No.

PCT/EP03/08704

**I. Basis of the report**

The basis of this international preliminary examination is the application as originally filed.

**V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability**

In light of the documents cited in the international search report, it is considered that the invention as defined in at least some of the claims does not appear to meet the criteria mentioned in Article 33(1) PCT, i.e. does not appear to be novel and/or to involve an inventive step (see international search report, in particular the documents cited X and/or Y and corresponding claim references).

524,198

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number  
WO 2004/018683 A1

(51) International Patent Classification<sup>7</sup>: C12N 15/31, C07K 14/315, C12N 1/21, 15/63

(74) Agent: KEUS, J., A., R.; P.O. Box 31, NL-5830 AA Boxmeer (NL).

(21) International Application Number:  
PCT/EP2003/008704

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 6 August 2003 (06.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
02078325.4 12 August 2002 (12.08.2002) EP

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): HENSEN, Selma, Marianne [NL/NL]; Generaal Gavinstraat 3, NL-6585 WL Mook (NL). NUIJTEN, Petrus, Johannes, Maria [NL/NL]; Radioweg 1, NL-5836 CD Sambeek (NL).

WO 2004/018683 A1

(54) Title: STREPTOCOCCUS UBERIS PROTEIN, NUCLEIC ACID SEQUENCE ENCODING THE SAME AND ITS USE IN A MASTITIS VACCINE

(57) Abstract: The present invention relates to nucleic acid sequences encoding a 22.5 kD *Streptococcus uberis* protein and to parts of such nucleic acid sequences that encode an immunogenic fragment of such proteins, and to DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof. The invention also relates to a 22.5 kD *Streptococcus uberis* protein and immunogenic parts thereof encoded by such sequences. Furthermore, the present invention relates to vaccines comprising such nucleic acid sequences and parts thereof, DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof, proteins or immunogenic parts thereof and antibodies against such proteins or immunogenic parts thereof. Also, the invention relates to the use of said proteins in vaccines and for the manufacture of vaccines. Moreover, the invention relates to the use of said nucleic acid sequences, proteins or antibodies for diagnostic or vaccination purposes. Finally the invention relates to diagnostic kits comprising such a nucleic acid, protein or antibodies against such protein.

BEST AVAILABLE COPY

## STREPTOCOCCUS UBERIS PROTEIN, NUCLEIC ACID SEQUENCE ENCODING THE SAME AND ITS USE IN A MASTITIS VACCINE

The present invention relates to nucleic acid sequences encoding a *Streptococcus uberis* protein and to parts of such nucleic acid sequences that encode an

5 immunogenic fragment of such proteins, and to DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof. The invention also relates to a *Streptococcus uberis* protein and immunogenic parts thereof encoded by such sequences.

Furthermore, the present invention relates to vaccines comprising such nucleic acid 10 sequences and parts thereof, DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof, proteins or immunogenic parts thereof and antibodies against such proteins or immunogenic parts thereof. Also, the invention relates to the use of said proteins in vaccines and for the manufacture of vaccines. Moreover, the invention 15 relates to the use of said nucleic acid sequences, proteins or antibodies for diagnostic or vaccination purposes. Finally the invention relates to diagnostic kits comprising such a nucleic acid, protein or antibodies against such protein.

Mastitis in cows is an inflammation of the mammary gland, that usually occurs after 20 intramammary infection. Mastitis is primarily caused by bacteria, although mycoplasmal, mycotic and algal infections are known to be able to cause mastitis as well.

Mastitis is the most costly disease in dairy cattle. The amount of money lost yearly in the USA only, exceeds \$2.000.000.000. The combined losses due to discarded milk 25 and decreased milk production is responsible for about 75% of the costs of mastitis, whereas loss of animals, labor costs and vet costs are responsible for about 25% of the total costs.

In principle, two types of mastitis are distinguished: contagious mastitis and environmental mastitis. Contagious mastitis is the type of mastitis that spreads from 30 one cow to the other. The most important pathogens involved in cow-to-cow mastitis are *Staphylococcus aureus*, *Streptococcus agalactiae* and *Mycoplasma*.

Environmental mastitis is the type of mastitis caused by pathogenic microorganisms found in the environment. The most common causes of environment-to-cow mastitis are on the one hand coliform bacteria such as *E. coli*, *Enterobacter*, *Klebsiella* and 35 *Citrobacter*, and on the other hand *Streptococcal* species such as *Streptococcus uberis* and *Streptococcus dysgalactiae*.

It is clear that mastitis is a multifactor disease and therefore several routes have to be followed in order to prevent or control mastitis. One of these routes is aiming at a microbiologically clean environment, which is highly desirable but practically impossible. Another one is the use of pharmaceutical components, such as the

5 extensive use of antibiotics, more precisely antibacterials which nowadays is a very common therapy in the treatment of mastitis.

Still another one is undoubtedly vaccination against the various pathogens involved in mastitis. It is thus clear that, especially where there is an increasing reluctance against the use of antibiotics, there is a need for new and effective vaccines,

10 especially vaccines that provide broad protection.

It is an objective of the present invention to provide a novel vaccine component for combating mastitis infection.

15 It was now surprisingly found that a novel *Streptococcus uberis* protein exists, that can be used as a valuable vaccine component, either alone or in combination with other vaccine components.

20 The gene encoding this protein has now been cloned and sequenced and its sequence is depicted in SEQ ID NO: 1. The gene encodes a protein of 200 amino acids (as depicted in SEQ ID NO: 2) with a molecular mass of 22.5 kD.

25 It is well-known in the art, that many different nucleic acid sequences can encode one and the same protein. This phenomenon is commonly known as wobble in the second and especially the third base of each triplet encoding an amino acid. This phenomenon can result in a heterology for two nucleic acid sequences still encoding the same protein. Therefore, two nucleic acid sequences having a sequence homology as low as 70 % can still encode one and the same protein.

30 Thus, one embodiment relates to a nucleic acid sequence encoding a 22.5 kD *Streptococcus uberis* protein or a part of said nucleic acid sequence that encodes an immunogenic fragment of said protein wherein said nucleic acid sequence or said part thereof has at least 85 % homology with the nucleic acid sequence of the 22.5 kD *Streptococcus uberis* protein gene as depicted in SEQ ID NO: 1.

The concept of immunogenic fragment is defined below. The length of a nucleic acid sequence encoding an immunogenic fragment is usually at least 21 nucleotides, but preferably 24, 27, 30, 33 or even 36 nucleotides.

5 The molecular weight of 22.5 kD is determined in gel electrophoresis on a polyacryl amide gel. Due to slight variability of molecular weight determination frequently encountered in the art, the molecular weight can vary between 19.5 and 25.5 kD. Therefore the molecular weight of the proteins according to the invention should be interpreted as to be 22.5 +/- 3 kD.

10

Preferably, a nucleic acid sequence according to the invention encoding this 22.5 *Streptococcus uberis* protein or a part of that nucleic acid sequence that encodes an immunogenic fragment of that protein has at least 90 %, preferably 93 %, more preferably 95 % homology with the nucleic acid sequence of the *Streptococcus*

15 *uberis* protein gene as depicted in SEQ ID NO: 1.

Even more preferred is a homology level of 98%, 99% or even 100%.

20 The level of nucleotide homology can be determined with the computer program "BLAST 2 SEQUENCES" by selecting sub-program: "BLASTN" that can be found at [www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html](http://www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html).

A reference for this program is Tatiana A. Tatusova, Thomas L. Madden FEMS Microbiol. Letters 174: 247-250 (1999). Parameters used are the default parameters: Reward for a match: +1. Penalty for a mismatch: -2. Open gap: 5. Extension gap: 2. 25 Gap x\_dropoff: 50.

Nucleotide sequences that are complementary to the sequence depicted in SEQ ID NO 1 or nucleotide sequences that comprise tandem arrays of the sequences according to the invention are also within the scope of the invention.

30

Since the present invention discloses nucleic acid sequences encoding a novel 22.5 kD *Streptococcus uberis* protein, it is now for the first time possible to obtain this protein in sufficient quantities. This can e.g. be done by using expression systems to express the whole or parts of the gene encoding the protein or an immunogenic fragment thereof.

35 Therefore, in a more preferred form of this embodiment, the invention relates to DNA fragments comprising a nucleic acid sequence according to the invention. A DNA

fragment is a stretch of nucleotides that functions as a carrier for a nucleic acid sequence according to the invention. Such DNA fragments can e.g. be plasmids, into which a nucleic acid sequence according to the invention is cloned. Such DNA fragments are e.g. useful for enhancing the amount of DNA for use as a primer and 5 for expression of a nucleic acid sequence according to the invention, as described below.

An essential requirement for the expression of the nucleic acid sequence is an adequate promoter functionally linked to the nucleic acid sequence, so that the 10 nucleic acid sequence is under the control of the promoter. It is obvious to those skilled in the art that the choice of a promoter extends to any eukaryotic, prokaryotic or viral promoter capable of directing gene transcription in cells used as host cells for protein expression.

Therefore, an even more preferred form of this embodiment relates to a recombinant 15 DNA molecule comprising a DNA fragment and/or a nucleic acid sequence according to the invention wherein the nucleic acid sequence according to the invention is placed under the control of a functionally linked promoter. This can be obtained by means of e.g. standard molecular biology techniques. (Maniatis/Sambrook (Sambrook, J. Molecular cloning: a laboratory manual, 1989. ISBN 0-87969-309-6).

Functionally linked promoters are promoters that are capable of controlling the 20 transcription of the nucleic acid sequences to which they are linked. Such a promoter can be the native promoter of the novel gene or another promoter of *Streptococcus uberis*, provided that that promoter is functional in the cell used for expression. It can also be a heterologous promoter. When the host cells are 25 bacteria, useful expression control sequences which may be used include the Trp promoter and operator (Goeddel, et al., Nucl. Acids Res., 8, 4057, 1980); the lac promoter and operator (Chang, et al., Nature, 275, 615, 1978); the outer membrane protein promoter (Nakamura, K. and Inouge, M., EMBO J., 1, 771-775, 1982); the bacteriophage lambda promoters and operators (Remaut, E. et al., Nucl. Acids Res., 30 11, 4677-4688, 1983); the  $\alpha$ -amylase (*B. subtilis*) promoter and operator, termination sequences and other expression enhancement and control sequences compatible with the selected host cell.

When the host cell is yeast, useful expression control sequences include, e.g.,  $\alpha$ -mating factor. For insect cells the polyhedrin or p10 promoters of baculoviruses can 35 be used (Smith, G.E. et al., Mol. Cell. Biol. 3, 2156-65, 1983). When the host cell is of vertebrate origin illustrative useful expression control sequences include the

(human) cytomegalovirus immediate early promoter (Seed, B. et al., *Nature* 329, 840-842, 1987; Fynan, E.F. et al., *PNAS* 90, 11478-11482, 1993; Ulmer, J.B. et al., *Science* 259, 1745-1748, 1993), Rous sarcoma virus LTR (RSV, Gorman, C.M. et al., *PNAS* 79, 6777-6781, 1982; Fynan et al., *supra*; Ulmer et al., *supra*), the MPSV 5 LTR (Stacey et al., *J. Virology* 50, 725-732, 1984), SV40 immediate early promoter (Sprague J. et al., *J. Virology* 45, 773, 1983), the SV-40 promoter (Berman, P.W. et al., *Science*, 222, 524-527, 1983), the metallothionein promoter (Brinster, R.L. et al., *Nature* 296, 39-42, 1982), the heat shock promoter (Voellmy et al., *Proc. Natl. Acad. Sci. USA*, 82, 4949-53, 1985), the major late promoter of Ad2 and the β-actin 10 promoter (Tang et al., *Nature* 356, 152-154, 1992). The regulatory sequences may also include terminator and poly-adenylation sequences. Amongst the sequences that can be used are the well known bovine growth hormone poly-adenylation sequence, the SV40 poly-adenylation sequence, the human cytomegalovirus (hCMV) terminator and poly-adenylation sequences.

15

Bacterial, yeast, fungal, insect and vertebrate cell expression systems are very frequently used systems. Such systems are well-known in the art and generally available, e.g. commercially through Clontech Laboratories, Inc. 4030 Fabian Way, Palo Alto, California 94303-4607, USA. Next to these expression systems, parasite-based expression systems are attractive expression systems. Such systems are e.g. described in the French Patent Application with Publication number 2 714 074, and in US NTIS Publication No US 08/043109 (Hoffman, S. and Rogers, W.: Public. Date 1 December 1993).

25

A still even more preferred form of this embodiment of the invention relates to Live Recombinant Carriers (LRCs) comprising a nucleic acid sequence encoding a 22.5 kD *Streptococcus uberis* protein or an immunogenic fragment thereof according to the invention, a DNA fragment according to the invention or a recombinant DNA molecule according to the invention. These LRCs are micro-organisms or viruses in which additional genetic information, in this case a nucleic acid sequence encoding the 22.5 kD *Streptococcus uberis* protein or an immunogenic fragment thereof according to the invention has been cloned. Cows infected with such LRCs will produce an immunological response not only against the immunogens of the carrier, but also against the immunogenic parts of the protein(s) for which the genetic code is additionally cloned into the LRC, e.g. the novel 22.5 kD *Streptococcus uberis* protein gene according to the invention.

As an example of bacterial LRCs, attenuated *Salmonella* strains known in the art can very attractively be used.

Also, live recombinant carrier parasites have i.a. been described by Vermeulen, A. N. (Int. Journ. Parasitol. 28: 1121-1130 (1998)).

- 5 Furthermore, LRC viruses may be used as a way of transporting the nucleic acid sequence into a target cell. Live recombinant carrier viruses are also called vector viruses. Viruses often used as vectors are *Vaccinia* viruses (Panicali et al; Proc. Natl. Acad. Sci. USA, 79: 4927 (1982), Herpesviruses (E.P.A. 0473210A2), and Retroviruses (Valerio, D. et al; in Baum, S.J., Dicke, K.A., Lotzova, E. and Pluznik, 10 D.H. (Eds.), Experimental Haematology today - 1988. Springer Verlag, New York: pp. 92-99 (1989)).

The technique of *in vivo* homologous recombination, well-known in the art, can be used to introduce a recombinant nucleic acid sequence into the genome of a

- 15 bacterium, parasite or virus of choice, capable of inducing expression of the inserted nucleic acid sequence according to the invention in the host animal.

Finally another form of this embodiment of the invention relates to a host cell comprising a nucleic acid sequence encoding a protein according to the invention, a

- 20 DNA fragment comprising such a nucleic acid sequence or a recombinant DNA molecule comprising such a nucleic acid sequence under the control of a functionally linked promoter. This form also relates to a host cell containing a live recombinant carrier comprising a nucleic acid molecule encoding a 22.5 kD *Streptococcus uberis* protein or an immunogenic fragment thereof according to the invention.

- 25 A host cell may be a cell of bacterial origin, e.g. *Escherichia coli*, *Bacillus subtilis* and *Lactobacillus* species, in combination with bacteria-based plasmids as pBR322, or bacterial expression vectors as the pEX-, pET-, pGEX-series, or with bacteriophages. The host cell may also be of eukaryotic origin, e.g. yeast-cells in combination with yeast-specific vector molecules, or higher eukaryotic cells like 30 insect cells (Luckow et al; Bio-technology 6: 47-55 (1988)) in combination with vectors or recombinant baculoviruses, plant cells in combination with e.g. Ti-plasmid based vectors or plant viral vectors (Barton, K.A. et al; Cell 32: 1033 (1983), mammalian cells like Hela cells, Chinese Hamster Ovary cells (CHO) or Crandell Feline Kidney-cells, also with appropriate vectors or recombinant viruses.

35

Another embodiment of the invention relates to the novel 22.5 kD *Streptococcus uberis* protein and to immunogenic fragments thereof according to the invention.

The concept of immunogenic fragments will be defined below.

One form of this embodiment relates to a 22.5 kD *Streptococcus uberis* protein and  
5 to immunogenic fragments thereof having a length of at least 33 amino acids,  
wherein the protein or immunogenic fragments have a sequence homology of at  
least 93%, preferably however 94%, more preferably 95% or even 96% homology, in  
that order or preference, to the amino acid sequence as depicted in SEQ ID NO: 2.  
  
10 Even more preferred is a homology level of 97%, 98%, 99% or even 100% in that  
order of preference.

The immunogenic fragments of the *Streptococcus uberis* protein according to the  
invention preferably have a length of at least 33, more preferably 35, 38, 41, 45 or  
15 even 50 amino acids, in that order of preference.

A more preferred form of this embodiment relates to a 22.5 kD *Streptococcus uberis*  
protein and immunogenic fragments of said protein, encoded by a nucleic acid  
sequence according to the present invention.

20 The level of protein homology can be determined with the computer program  
"BLAST 2 SEQUENCES" by selecting sub-program: "BLASTP", that can be found at  
[www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html](http://www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html).  
A reference for this program is Tatiana A. Tatusova, Thomas L. Madden FEMS  
25 Microbiol. Letters 174: 247-250 (1999). Matrix used: "blosum62". Parameters used  
are the default parameters:  
Open gap: 11. Extension gap: 1. Gap x\_dropoff: 50.

It will be understood that, for the particular proteins embraced herein, natural  
30 variations can exist between individual *Streptococcus uberis* strains. These  
variations may be demonstrated by (an) amino acid difference(s) in the overall  
sequence or by deletions, substitutions, insertions, inversions or additions of (an)  
amino acid(s) in said sequence. Amino acid substitutions which do not essentially  
alter biological and immunological activities, have been described, e.g. by Neurath et  
35 al in "The Proteins" Academic Press New York (1979). Amino acid replacements  
between related amino acids or replacements which have occurred frequently in  
evolution are, inter alia, Ser/Ala, Ser/Gly, Asp/Gly, Asp/Asn, Ile/Val (see Dayhof,

M.D., *Atlas of protein sequence and structure*, Nat. Biomed. Res. Found., Washington D.C., 1978, vol. 5, suppl. 3). Other amino acid substitutions include Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Thr/Phe, Ala/Pro, Lys/Arg, Leu/Ile, Leu/Val and Ala/Glu. Based on this information, Lipman and Pearson  
5 developed a method for rapid and sensitive protein comparison (*Science*, 227, 1435-1441, 1985) and determining the functional similarity between homologous proteins. Such amino acid substitutions of the exemplary embodiments of this invention, as well as variations having deletions and/or insertions are within the scope of the invention as long as the resulting proteins retain their immune reactivity.  
10 This explains why *Streptococcus uberis* proteins according to the invention, when isolated from different field isolates, may have homology levels of about 70%, while still representing the same protein with the same immunological characteristics. Those variations in the amino acid sequence of a certain protein according to the invention that still provide a protein capable of inducing an immune response against  
15 infection with *Streptococcus uberis* or at least against the clinical manifestations of the infection are considered as "not essentially influencing the immunogenicity".

When a protein is used for e.g. vaccination purposes or for raising antibodies, it is however not necessary to use the whole protein. It is also possible to use a fragment 20 of that protein that is capable, as such or coupled to a carrier such as e.g. KLH, of inducing an immune response against that protein, a so-called immunogenic fragment. An "immunogenic fragment" is understood to be a fragment of the full-length protein that still has retained its capability to induce an immune response in a vertebrate host, e.g. comprises a B- or T-cell epitope. Shortly, an immunogenic  
25 fragment is a fragment that is capable of inducing an antigenic response against the 22.5 kD *Streptococcus uberis* protein according to the invention. At this moment, a variety of techniques is available to easily identify DNA fragments encoding antigenic fragments (determinants). The method described by Geysen et al (Patent Application WO 84/03564, Patent Application WO 86/06487, US Patent NR. 4,833,092, Proc.  
30 Natl Acad. Sci. 81: 3998-4002 (1984), J. Imm. Meth. 102, 259-274 (1987), the so-called PEPSCAN method is an easy to perform, quick and well-established method for the detection of epitopes; the immunologically important regions of the protein. The method is used world-wide and as such well-known to man skilled in the art. This (empirical) method is especially suitable for the detection of B-cell epitopes.  
35 Also, given the sequence of the gene encoding any protein, computer algorithms are able to designate specific protein fragments as the immunologically important epitopes on the basis of their sequential and/or structural agreement with epitopes

that are now known. The determination of these regions is based on a combination of the hydrophilicity criteria according to Hopp and Woods (Proc. Natl. Acad. Sci. 78: 38248-3828 (1981)), and the secondary structure aspects according to Chou and Fasman (Advances in Enzymology 47: 45-148 (1987) and US Patent 4,554,101). T-cell epitopes can likewise be predicted from the sequence by computer with the aid of Berzofsky's amphiphilicity criterion (Science 235, 1059-1062 (1987) and US Patent application NTIS US 07/005,885). A condensed overview is found in: Shan Lu on common principles: Tibtech 9: 238-242 (1991), Good et al on Malaria epitopes; Science 235: 1059-1062 (1987), Lu for a review; Vaccine 10: 3-7 (1992), Berzofsky for HIV-epitopes; The FASEB Journal 5:2412-2418 (1991). An immunogenic fragment usually has a minimal length of 6, more commonly 8 amino acids, preferably more than 8, such as 9, 10, 12, 15 or even 20 or more amino acids. The nucleic acid sequences encoding such a fragment therefore have a length of at least 18, more commonly 24 and preferably 27, 30, 36, 45 or even 60 nucleic acids.

Therefore, one form of still another embodiment of the invention relates to vaccines for combating *Streptococcus uberis* infection, that comprise a 22.5 kD *Streptococcus uberis* protein or immunogenic fragments thereof, according to the invention as described above together with a pharmaceutically acceptable carrier.

Still another embodiment of the present invention relates to the 22.5 kD *Streptococcus uberis* protein according to the invention or immunogenic fragments thereof for use in a vaccine.

Again another embodiment of the present invention relates to the use of a 22.5 kD *Streptococcus uberis* protein, or an immunogenic fragment of that protein having a length of at least 6 amino acids, wherein that protein or immunogenic fragment thereof has an amino acid sequence homology of at least 70%, preferably 80%, more preferably 85% with the amino acid sequence as depicted in SEQ ID NO: 2 for the manufacturing of a vaccine for combating *Streptococcus uberis* infection.

Even more preferred is a sequence homology of 90%, 95%, 97%, 98%, 99% or even 100% in that order of preference.

Still another embodiment of the present invention relates to the use of a nucleic acid sequence, a DNA fragment, a recombinant DNA molecule, a live recombinant carrier, a host cell or a protein or an immunogenic fragment thereof according to the

invention for the manufacturing of a vaccine, more specifically a vaccine for combating *Streptococcus uberis* infection.

One way of making a vaccine according to the invention is by growing the bacteria,  
5 followed by biochemical purification of the 22.5 kD *Streptococcus uberis* protein or immunogenic fragments thereof, from the bacterium. This is however a very time-consuming way of making the vaccine.

It is therefore much more convenient to use the expression products of the gene  
10 encoding a 22.5 kD *Streptococcus uberis* protein or immunogenic fragments thereof in vaccines. This is possible for the first time now because the nucleic acid sequence of the gene encoding a 22.5 kD protein is provided in the present invention.

Vaccines based upon the expression products of these genes can easily be made by  
15 admixing the protein according to the invention or immunogenic fragments thereof according to the invention with a pharmaceutically acceptable carrier as described below.

Alternatively, a vaccine according to the invention can comprise live recombinant  
20 carriers as described above, capable of expressing the protein according to the invention or immunogenic fragments thereof. Such vaccines, e.g. based upon a *Salmonella* carrier or a viral carrier e.g. a Herpesvirus vector have the advantage over subunit vaccines that they better mimic the natural way of infection of *Streptococcus uberis*. Moreover, their self-propagation is an advantage since only  
25 low amounts of the recombinant carrier are necessary for immunization.

Vaccines can also be based upon host cells as described above, that comprise the protein or immunogenic fragments thereof according to the invention.

30 All vaccines described above contribute to active vaccination, i.e. they trigger the host's defense system.

Alternatively, antibodies can be raised in e.g. rabbits or can be obtained from antibody-producing cell lines as described below. Such antibodies can then be administered to the cow. This method of vaccination, passive vaccination, is the  
35 vaccination of choice when an animal is already infected, and there is no time to allow the natural immune response to be triggered. It is also the preferred method for vaccinating animals that are prone to sudden high infection pressure. The

administered antibodies against the protein according to the invention or immunogenic fragments thereof can in these cases interfere with *Streptococcus uberis*. This has the advantage that it decreases or stops *Streptococcus uberis* multiplication.

5 Therefore, one other form of this embodiment of the invention relates to a vaccine for combating *Streptococcus uberis* infection that comprises antibodies against a *Streptococcus uberis* protein according to the invention or an immunogenic fragment of that protein, and a pharmaceutically acceptable carrier.

10 Still another embodiment of this invention relates to antibodies against a *Streptococcus uberis* protein according to the invention or an immunogenic fragment of that protein.

15 Methods for large-scale production of antibodies according to the invention are also known in the art. Such methods rely on the cloning of (fragments of) the genetic information encoding the protein according to the invention in a filamentous phage for phage display. Such techniques are described i.a. at the "Antibody Engineering Page" under "filamentous phage display" at <http://aximt1.imt.uni-marburg.de/~rek/aepphage.html>, and in review papers by Cortese, R. et al., (1994) in Trends Biotechn. 12: 262-267., by Clackson, T. & Wells, J.A. (1994) in Trends Biotechn. 12: 173-183, by Marks, J.D. et al., (1992) in J. Biol. Chem. 267: 16007-16010, by Winter, G. et al., (1994) in Annu. Rev. Immunol. 12: 433-455, and by Little, M. et al., (1994) Biotechn. Adv. 12: 539-555. The phages are subsequently used to screen camelid expression libraries expressing camelid heavy chain antibodies. 20 (Muyldermans, S. and Lauwereys, M., Journ. Molec. Recogn. 12: 131-140 (1999) and Ghahroudi, M.A. et al., FEBS Letters 414: 512-526 (1997)). Cells from the library that express the desired antibodies can be replicated and subsequently be used for large scale expression of antibodies.

25 30 Still another embodiment relates to a method for the preparation of a vaccine according to the invention that comprises the admixing of antibodies according to the invention and a pharmaceutically acceptable carrier.

An alternative and efficient way of vaccination is direct vaccination with DNA encoding the relevant antigen. Direct vaccination with DNA encoding proteins has been successful for many different proteins. (As reviewed in e.g. Donnelly et al., The Immunologist 2: 20-26 (1993)). This way of vaccination is also attractive for the

vaccination of cows against *Streptococcus uberis* infection. Therefore, still other forms of this embodiment of the invention relate to vaccines comprising nucleic acid sequences encoding a protein according to the invention or immunogenic fragments thereof, comprising DNA fragments that comprise such nucleic acid sequences or 5 comprising recombinant DNA molecules according to the invention, and a pharmaceutically acceptable carrier.

Examples of DNA plasmids that are suitable for use in a DNA vaccine according to the invention are conventional cloning or expression plasmids for bacterial, 10 eukaryotic and yeast host cells, many of said plasmids being commercially available. Well-known examples of such plasmids are pBR322 and pcDNA3 (Invitrogen). The DNA fragments or recombinant DNA molecules according to the invention should be able to induce protein expression of the nucleotide sequences. The DNA fragments or recombinant DNA molecules may comprise one or more nucleotide sequences 15 according to the invention. In addition, the DNA fragments or recombinant DNA molecules may comprise other nucleotide sequences such as the immune-stimulating oligonucleotides having unmethylated CpG di-nucleotides, or nucleotide sequences that code for other antigenic proteins or adjuvating cytokines.

20 The nucleotide sequence according to the present invention or the DNA plasmid comprising a nucleotide sequence according to the present invention, preferably operably linked to a transcriptional regulatory sequence, to be used in the vaccine according to the invention can be naked or can be packaged in a delivery system. Suitable delivery systems are lipid vesicles, iscoms, dendromers, niosomes, 25 polysaccharide matrices and the like, (see further below) all well-known in the art. Also very suitable as delivery system are attenuated live bacteria such as *Salmonella* species, and attenuated live viruses such as Herpesvirus vectors, as mentioned above.

30 Still other forms of this embodiment relate to vaccines comprising recombinant DNA molecules according to the invention.

DNA vaccines can e.g. easily be administered through intradermal application such as by using a needle-less injector. This way of administration delivers the DNA 35 directly into the cells of the animal to be vaccinated. Amounts of DNA in the range between 10 pg and 1000 µg provide good results. Preferably, amounts in the microgram range between 1 and 100 µg are used.

In a further embodiment, the vaccine according to the present invention additionally comprises one or more antigens derived from cow pathogenic organisms and viruses, antibodies against those antigens or genetic information encoding such

5       antigens and/or a pharmaceutical component such as an antibiotic.

Of course, such antigens, antibodies against such antigens, or genetic information can be of *Streptococcus uberis* origin, such as e.g. another *Streptococcus uberis* antigen. It can also be an antigen, antibodies or genetic information selected from another cow pathogenic organism or virus. Such organisms and viruses are

10     preferably selected from the group of Bovine Herpesvirus, bovine Viral Diarrhoea virus, Parainfluenza type 3 virus, Bovine Paramyxovirus, Foot and Mouth Disease virus, *Pasteurella haemolytica*, Bovine Respiratory Syncytial Virus, *Theileria* sp., *Babesia* sp., *Trypanosoma* species, *Anaplasma* sp., *Neospora caninum*, *Staphylococcus aureus*, *Streptococcus agalactiae*, Mycoplasma, *E. coli*,

15     *Enterobacter*, *Klebsiella*, *Citrobacter* and *Streptococcus dysgalactiae*.

Vaccines based upon the 22.5 kD *Streptococcus uberis* protein are also very suitable as marker vaccines. A marker vaccine is a vaccine that allows to discriminate between vaccinated and field-infected cows e.g. on the basis of a

20     characteristic antibody panel, different from the antibody panel induced by wild type infection. A different antibody panel is induced e.g. when an immunogenic protein present on a wild type bacterium is not present in a vaccine: the host will then not make antibodies against that protein after vaccination. Thus, a vaccine based upon the 22.5 kD *Streptococcus uberis* protein according to the invention would only

25     induce antibodies against the 22.5 kD protein, whereas a vaccine based upon a live wild-type, live attenuated or inactivated whole *Streptococcus uberis* would induce antibodies against all or most of the bacterial proteins.

A simple ELISA test, having wells comprising e.g. another, i.e. non-22.5 kD *Streptococcus uberis* protein and wells comprising only purified 22.5 kD

30     *Streptococcus uberis* protein suffices to test serum from cows and to tell if the cows are either vaccinated with the 22.5 kD protein vaccine or suffered from *Streptococcus uberis* field infection.

All vaccines according to the present invention comprise a pharmaceutically

35     acceptable carrier. A pharmaceutically acceptable carrier can be e.g. sterile water or a sterile physiological salt solution. In a more complex form the carrier can e.g. be a buffer.

Methods for the preparation of a vaccine comprise the admixing of a protein or an immunogenic fragment thereof, according to the invention and/or antibodies against that protein or an immunogenic fragment thereof, and/or a nucleic acid sequence and/or a DNA fragment, a recombinant DNA molecule, a live recombinant carrier or host cell according to the invention, and a pharmaceutically acceptable carrier.

Vaccines according to the present invention may in a preferred presentation also contain an immunostimulatory substance, a so-called adjuvant. Adjuvants in general comprise substances that boost the immune response of the host in a non-specific manner. A number of different adjuvants are known in the art. Examples of adjuvants frequently used in cow vaccines are muramyldipeptides, lipopolysaccharides, several glucans and glycans and Carbopol(R) (a homopolymer).

The vaccine may also comprise a so-called "vehicle". A vehicle is a compound to which the protein adheres, without being covalently bound to it. Such vehicles are i.a. bio-microcapsules, micro-algicates, liposomes and macrosols, all known in the art.

A special form of such a vehicle, in which the antigen is partially embedded in the vehicle, is the so-called ISCOM (EP 109.942, EP 180.564, EP 242.380)

In addition, the vaccine may comprise one or more suitable surface-active compounds or emulsifiers, e.g. Span or Tween.

Often, the vaccine is mixed with stabilisers, e.g. to protect degradation-prone proteins from being degraded, to enhance the shelf-life of the vaccine, or to improve freeze-drying efficiency. Useful stabilisers are i.a. SPGA (Bovarnik et al; J. Bacteriology 59: 509 (1950)), carbohydrates e.g. sorbitol, mannitol, trehalose, starch, sucrose, dextran or glucose, proteins such as albumin or casein or degradation products thereof, and buffers, such as alkali metal phosphates.

In addition, the vaccine may be suspended in a physiologically acceptable diluent. It goes without saying, that other ways of adjuvating, adding vehicle compounds or diluents, emulsifying or stabilising a protein are also embodied in the present invention.

Vaccines according to the invention that are based upon the protein according to the invention or immunogenic fragments thereof can very suitably be administered in amounts ranging between 1 and 100 micrograms of protein per animal, although

smaller doses can in principle be used. A dose exceeding 100 micrograms will, although immunologically very suitable, be less attractive for commercial reasons.

Vaccines based upon live attenuated recombinant carriers, such as the LRC-viruses  
5 and bacteria described above can be administered in much lower doses, because they multiply themselves during the infection. Therefore, very suitable amounts would range between  $10^3$  and  $10^9$  CFU/PFU for both bacteria and viruses.

Vaccines according to the invention can be administered e.g. intradermally,  
10 subcutaneously, intramuscularly, intraperitoneally, intravenously, or at mucosal surfaces such as orally or intranasally.

For efficient protection against disease, a quick and correct diagnosis of *Streptococcus uberis* infection is important.

15 Therefore it is another objective of this invention to provide diagnostic tools suitable for the detection of *Streptococcus uberis* infection.

The nucleic acid sequences, the proteins and the antibodies according to the invention are also suitable for use in diagnostics.

20 Therefore, another embodiment of the invention relates to nucleic acid sequences, proteins and antibodies according to the invention for use in diagnostics.

25 The nucleic acid sequences or fragments thereof according to the invention can be used to detect the presence of *Streptococcus uberis* in cows. A sample taken from cows infected with *Streptococcus uberis* will comprise nucleic acid material derived from said bacterium, including nucleic acid sequences encoding for the protein according to the invention. These nucleic acid sequences will hybridize with a nucleic acid sequence according to the invention. Suitable methods for the detection of  
30 nucleic acid sequences that are reactive with the nucleic acid sequences of the present invention include hybridization techniques including but not limited to PCR techniques and NASBA techniques. Thus the nucleic acid sequences according to the invention, in particular the sequence depicted in SEQ ID NO 1 can be used to prepare probes and primers for use in PCR and or NASBA techniques.

35 A diagnostic test kit for the detection of *Streptococcus uberis* may e.g. comprise tools to enable the reaction of bacterial nucleic acid isolated from the cows to be tested with these tools. Such tools are e.g. specific probes or (PCR-) primers, also referred

to as primer fragments, based upon the nucleic acid sequences according to the invention. If genetic material of *Streptococcus uberis* is present in the animal, this will e.g. specifically bind to specific PCR-primers and, e.g. after cDNA synthesis, will subsequently become amplified in PCR-reaction. The PCR-reaction product can then 5 easily be detected in DNA gel electrophoresis.

Standard PCR-textbooks give methods for determining the length of the primers for selective PCR-reactions with *Streptococcus uberis* DNA. Primer fragments with a nucleotide sequence of at least 12 nucleotides are frequently used, but primers of more than 15, more preferably 18 nucleotides are somewhat more selective.

10 Especially primers with a length of at least 20, preferably at least 30 nucleotides are very generally applicable. PCR-techniques are extensively described in Dieffenbach & Dreksler; PCR primers, a laboratory manual. ISBN 0-87969-447-5 (1995).

Nucleic acid sequences according to the invention or primers of those nucleic acid sequences having a length of at least 12, preferably 15, more preferably 18, even 15 more preferably 20, 22, 25, 30, 35 or 40 nucleotides in that order of preference, wherein the nucleic acid sequences or parts thereof have at least 70 % homology with the nucleic acid sequence as depicted in SEQ ID NO: 1 are therefore also part of the invention. Primers are understood to have a length of at least 12 nucleotides and a homology of at least 70%, more preferably 80%, 85%, 90%, 95%, 98%, 99% 20 or even 100%, in that order of preference, with the nucleic acid sequence as depicted in SEQ ID NO: 1. Such nucleic acid sequences can be used as primer fragments in PCR-reactions in order to enhance the amount of DNA that they encode or in hybridization reactions. This allows the quick amplification or detection on blots of specific nucleotide sequences for use as a diagnostic tool for e.g. the 25 detection of *Streptococcus uberis* as indicated above.

Another test on genetic material is based upon growth of bacterial material obtained from e.g. a swab, followed by classical DNA purification followed by classical hybridization with radioactively or color-labeled primer fragments. Colour-labelled and radioactively labeled fragments are generally called detection means. Both 30 PCR-reactions and hybridization reactions are well-known in the art and are i.a. described in Maniatis/Sambrook (Sambrook, J. et al. Molecular cloning: a laboratory manual. ISBN 0-87969-309-6).

35 Thus, one embodiment of the invention relates to a diagnostic test kit for the detection of *Streptococcus uberis* nucleic acid sequences. Such a test comprises a nucleic acid sequence according to the invention or a primer fragment thereof.

A diagnostic test kit based upon the detection of antigenic material of the specific *Streptococcus uberis* 22.5 kD protein and therefore suitable for the detection of *Streptococcus uberis* infection may i.a. comprise a standard ELISA test. In one

5 example of such a test the walls of the wells of an ELISA plate are coated with antibodies directed against the 22.5 kD protein. After incubation with the material to be tested, labeled anti- *Streptococcus uberis* antibodies are added to the wells. A color reaction then reveals the presence of antigenic material from *Streptococcus uberis*.

10 Therefore, still another embodiment of the present invention relates to diagnostic test kits for the detection of antigenic material of *Streptococcus uberis*. Such test kits comprise antibodies against a 22.5 kD protein or a fragment thereof according to the invention.

15 A diagnostic test kit based upon the detection in serum of antibodies against the 22.5 kD protein of *Streptococcus uberis* and therefore suitable for the detection of *Streptococcus uberis* infection may i.a. comprise a standard ELISA test. In such a test the walls of the wells of an ELISA plate can e.g. be coated with the 22.5 kD protein. After incubation with the material to be tested, labeled anti-22.5 kD

20 antibodies are added to the wells. A lack of color reaction then reveals the presence of antibodies against *Streptococcus uberis*.

Therefore, still another embodiment of the present invention relates to diagnostic test kits for the detection of antibodies against *Streptococcus uberis*. Such test kits comprise the 22.5 kD *Streptococcus uberis* protein or a fragment thereof according

25 to the invention.

The design of the immunoassay may vary. For example, the immunoassay may be based upon competition or direct reaction. Furthermore, protocols may use solid supports or may use cellular material. The detection of the antibody-antigen complex

30 may involve the use of labeled antibodies; the labels may be, for example, enzymes, fluorescent-, chemoluminescent-, radio-active- or dye molecules.

Suitable methods for the detection of antibodies reactive with a protein according to the present invention in the sample include the enzyme-linked immunosorbent assay (ELISA), immunofluorescence test (IFT) and Western blot analysis.

35

The proteins or immunogenic fragments thereof according to the invention e.g. expressed as indicated above can be used to produce antibodies, which may be

polyclonal, monospecific or monoclonal (or derivatives thereof). If polyclonal antibodies are desired, techniques for producing and processing polyclonal sera are well-known in the art (e.g. Mayer and Walter, eds. *Immunochemical Methods in Cell and Molecular Biology*, Academic Press, London, 1987).

- 5 Monoclonal antibodies, reactive against the protein according to the invention or an immunogenic fragment thereof according to the present invention, can be prepared by immunizing inbred mice by techniques also known in the art (Kohler and Milstein, *Nature*, 256, 495-497, 1975).

### Examples.

#### EXAMPLE 1

##### Cloning and expression of the gene encoding the 22.5 kDa S. uberis protein

5 The amino acid sequence of the 22.5 kDa protein according to the invention contains a hydrophobic N-terminal signal sequence of 21 residues (SEQ ID 2). For expression in *E.coli* this domain was deleted and an expression construct was made in a pET-derived vector pETHis1 (ampicillin-resistance), which was constructed using a standard pET-vector as known in the art, into which i.a. several histidines were  
10 introduced. Figure 1 gives the sequence of the relevant region comprising a T7-promoter and several histidines at the 5'- and 3'-end of the multicloning site. The DNA fragment encoding residues 22 – 200 of the 22.5 kDa protein was amplified by PCR using a forward primer  
(CATgCCATgggg**CATA**TgTATATAACACATCAAAATgTAC), that started at residu  
15 22 (codon underlined) with an additional *Nde*I restriction site (bold italics) and a reverse primer (gCggg**ATCC**AAATTAgATAATAATTgTATg) that contained the last 22 nucleotides of the gene (underlined), lacking the TAA stop codon but with an additional *Bam*H I restriction site. Oligonucleotides were purchased from Gibco (BRL Life Technologies Inc., USA). This cloning strategy results in an expression product  
20 with a 6xHIS tag at the N-terminus and a 10xHIS tag at the C-terminus, which could be efficiently used for purification of the protein by means of metal affinity columns. PCR amplification was performed using a PE GeneAmp PCR system 9700 (Perkin Elmer, California, USA). The PCR mixture consisted of 20 U/ml Supertaq, 1 x Supertaq buffer, 80 µM (each) of dATP, dCTP, dGTP, dTTP (HT Biotechnology, Ltd, Cambridge, UK), 10 pmoles of the used primers and 1 µl of the chromosomal DNA of *S. uberis* as a template in a total volume of 50 µl. PCR was performed using the following program: denaturation for 2 minutes at 95°C, followed by 30 cycles consisting of 30 seconds denaturation at 95°C, 30 seconds annealing at 45°C and 1 minute elongation at 72°C, ending with 7 minutes 72°C and cooling down to 4°C.  
25  
30 The size of this PCR fragment was confirmed by agarose gel electrophoresis and the band was excized from gel and purified using the Qiaquick gel extraction kit (Qiagen, Inc, CA, USA). The PCR fragment was digested with *Nde*I and *Bam*H I and cloned into the pETHIS1 vector using *Nde*I and *Bam*H I restriction sites, giving the plasmid pETHis1-USP22.5.  
35 The ligation mixture was transformed into an appropriate *E. coli* host and clones were selected and verified for the correct insertion of the gene by nucleotide sequence analysis. Cycle sequencing reactions were carried out using a PE GeneAmp PCR

system 9700 (Perkin Elmer, Ca, USA). The cycle sequencing reaction mix consisted of approximately 375 ng of miniprep DNA or approximately 75 ng PCR-product (PCR-primers should be removed), 8  $\mu$ l Big dye Terminator Ready Reaction mix (Perkin Elmer, Ca, USA), 2.5 pmol primer in a total volume of 20  $\mu$ l. Cycle sequence reaction 5 was performed using the following program; 25 cycles with 10 seconds 95°C, 5 seconds 50°C and 4 minutes 60°C and then 4°C. The unincorporated dyes were removed by the Dye Ex Spin Kit (Qiagen, Inc, CA, USA). The nucleotide sequences were determined using an ABI 310 Automatic Sequencer. Sequence analysis was performed using sequencher version 4.0.5 (Gene Codes Corporation, Michigan, 10 USA).

Plasmid DNA of correct pETHis1-USP22.5 clones was isolated and transformed into *Escherichia coli* host strain BL21 Star<sup>TM</sup> (DE3) containing vector pLysS [genotype: F, *ompT*, *hsdS<sub>B</sub>* (*r<sub>b</sub>-*, *m<sub>B</sub>-*), *gal*, *dcm*, *me131* (DE3) *pLysS* (*Cam<sup>R</sup>*)]. *E. coli* strain BL21 Star (DE3) containing the plasmid pLysS and pETHis1-USP22.5 was grown 15 overnight at 30°C or 37°C and 200 rpm in 5 ml Terrific Broth (Sambrook et al. 1989. Molecular Cloning; a laboratory manual. Cold Spring Harbor Laboratory. Cold Spring Harbor, N.Y.) with 100  $\mu$ g/ml ampicillin, 25  $\mu$ g/ml chloramphenicol and 5 mM MgSO<sub>4</sub>. This overnight culture was diluted 1:50 in 50 ml of the same fresh medium. These cultures were grown under the same conditions until the OD<sub>600</sub> had reached 0.5, 20 measured at 600 nm on a NovaspecII spectrophotometer (Pharmacia). At this point a 100  $\mu$ l sample was taken for analysis. At OD<sub>600</sub> of 0.5 the cultures were induced with IPTG to a final concentration of 0.1 mM and continued to grow for a subsequent 3 hours. Again, a 100  $\mu$ l sample was taken for analysis. The samples were analysed 25 on a NuPAGE<sup>TM</sup> electrophoresis System by SDS-PAGE. The gels were stained with Coomassie Brilliant Blue (CBB).

Figure 2 shows a photograph of a CBB stained gel with a clear protein band of approximately 23 kDa in the lane of induced culture, which is absent in the control lane before IPTG induction. In conclusion it can be said that the 22.5 kDa protein of *S. uberis* can be efficiently expressed as a HIS-tagged protein in *E.coli*.

30

#### Metal Affinity Purification of HIS-tagged proteins

The bacterial pellet of 50 ml induction culture was defrozen at 37°C for 5 minutes. The pellet was resuspended in 20 ml lysisbuffer (8M Urea, 100 mM NaCl, 50 mM NaH<sub>2</sub>PO<sub>4</sub>, 10 mM TrisHCl pH8.0) and incubated on room 35 temperature for 15 minutes. A sample of the lysis mixture was saved for further analysis Add 1.5 ml of the lysis mixture to a Talon spin column

(Clontech, Palo Alto, California, USA). The His fusion protein was allowed to bind to the resin for 5 minutes. The column was centrifuge for 2 minutes at 700 x g. The eluate was saved for further analysis. The column with the bound fusion protein was washed three times with 1 ml lysisbuffer. The flow 5 throughs of the wash step were saved for further analysis. The bound protein was eluted in 2 steps using 6 M urea and 100 mM EDTA buffer. Using this method the 22.d kDa protein could be purified from the *E. coli* lysate (data not shown).

10 EXAMPLE 2

Immunoblotting of the expressed 22.5 kD protein

In order to show reactivity of the *E.coli* 22.5 kDa expression product, an immunoblot was done.

Purified, His-tagged 22.5 kDa protein was run on a protein gel along with *S. uberis* 15 proteins. *S. uberis* was grown under standard conditions and then treated with mutanolysin, an emzyme that degrades the cell wall of streptococcal species. In this way, cell wall associated proteins will be released. After centrifugation these released proteins will be present in the supernatant. Both, supernatant and cell pellet were run on the protein gel.

20 After electrophoresis of the purified 22.5 kD protein and the *S. uberis* proteins, the gel was blotted onto nitrocellulose membrane and then incubated with 1:1000 diluted antiserum from a cow suffering from *S. uberis* mastitis. Bovine antibodies reacting with *S. uberis* and *E.coli* proteins were stained with anti-bovine conjugated alkaline phosphatase.

25 In the lane comprising the purified 22.5 kDa expression product a clear band of approximately 23 kDa was visible. In Western immunoblotting this band reacted positive with antibodies from *S.uberis* infected cows (see Fig. 2 lane 6). In addition a band with a similar molecular weight was observed in lanes 3 and 5 which contained supernatant of mutanolysin treated *S. uberis* cells. Slight differences in molecular 30 weight are caused by the extra HIS residues of the *E. coli* expression product. This indicates that the 22.5 kDa protein is located in the cell wall or on the surface of *S. uberis* cells.

In conclusion, the 22.5 kD *Streptococcus uberis* protein according to the invention 35 can be efficiently expressed and subsequently isolated, and immunoreacts with

antiserum from *Streptococcus uberis* infected cows to a level comparable with the native 22.5 kD protein.

Legend to the figures.

Figure 1. Section of the pETHIS1 vector containing the T7 promoter and multiple cloning site with two HIS tags: 6xHIS at N-terminus and 10xHIS at C-terminus.

5

Figure 2. SDS-PAGE gel showing expression in *E. coli* of the 22.5 kD *Streptococcus uberis* protein.

Lane 1 shows the marker proteins and their molecular weight. Lane 2, marked "before" shows a whole cell preparation before induction of expression. Lane 3,

10 marked "after" shows a whole cell preparation after induction of expression. A clear 22.5 kD band (marked with an arrow) is seen in the lane marked "after" on the SDS-PAGE gel.

Figure 3. Western blot of the 22.5 kD *Streptococcus uberis* protein expressed in *E.*

15 *coli*.

Lane 1: MW markers, lane 2: *S. uberis* strain 024 pellet after mutanolysin treatment, lane 3: *S.uberis* strain 024 supernatant after mutanolysin treatment, lane 4: *S. uberis* strain 629 pellet after mutanolysin treatment, lane 5: *S.uberis* strain 629 supernatant after mutanolysin treatment , lane 6: HIS-tagged 22.5 kDa protein, purified from

20 *E.coli* cells.

25

## Claims

- 1) Nucleic acid sequence encoding a 22.5 kD *Streptococcus uberis* protein or a part of said nucleic acid sequence that encodes an immunogenic fragment of said protein, said nucleic acid sequence or said part thereof having at least 85 % homology with the nucleic acid sequence of the *Streptococcus uberis* protein gene as depicted in SEQ ID NO: 1.
- 2) Nucleic acid sequence or part thereof according to claim 1, characterized in that the sequence has at least 90 %, preferably 93 %, more preferably 95 % homology with the nucleic acid sequence of the *Streptococcus uberis* protein gene as depicted in SEQ ID NO: 1
- 3) DNA fragment comprising a nucleic acid sequence according to claim 1 or 2.
- 4) Recombinant DNA molecule comprising a nucleic acid sequence according to claim 1 or 2 or a DNA fragment according to claim 3, under the control of a functionally linked promoter.
- 5) Live recombinant carrier comprising a nucleic acid sequence according to claim 1 or 2, a DNA fragment according to claim 3 or a recombinant DNA molecule according to claim 4.
- 6) Host cell comprising a nucleic acid sequence according to claim 1 or 2, a DNA fragment according to claim 3, a recombinant DNA molecule according to claim 4 or a live recombinant carrier according to claim 5.
- 7) A 22.5 kD *Streptococcus uberis* protein or an immunogenic fragment of said protein having a length of at least 33 amino acids, characterized in that said protein or immunogenic fragment thereof has a sequence homology of at least 93 % to the amino acid sequence as depicted in SEQ ID NO: 2.
- 8) A 22.5 kD *Streptococcus uberis* protein or an immunogenic fragment thereof according to claim 7, having an amino acid sequence homology of at least 94%, preferably 95 %, more preferably 96% to the amino acid sequence as depicted in SEQ ID NO: 2.

9) A 22.5 kD *Streptococcus uberis* protein or an immunogenic fragment of said protein, according to claim 7 or 8, characterized in that said protein or immunogenic fragment is encoded by a nucleic acid sequence according to claim 1 or 2.

5 10) A 22.5 kD *Streptococcus uberis* protein or an immunogenic fragment thereof, according to claims 7-9 for use in a vaccine.

11) Use of a 22.5 kD *Streptococcus uberis* protein, or an immunogenic fragment of said protein having a length of at least 6 amino acids, said protein or immunogenic  
10 fragment thereof having an amino acid sequence homology of at least 70%, preferably 80%, more preferably 85% with the amino acid sequence as depicted in SEQ ID NO: 2 for the manufacturing of a vaccine for combating *Streptococcus uberis* infection.

15 12) Use of a nucleic acid sequence according to claim 1 or 2, a DNA fragment according to claim 3, a recombinant DNA molecule according to claim 4, a live recombinant carrier according to claim 5, a host cell according to claim 6 or a protein according to claims 7-9 or an immunogenic fragment thereof for the manufacturing of a vaccine for combating *Streptococcus uberis* infection.

20 13) Vaccine for combating *Streptococcus uberis* infection, characterized in that said vaccine comprises a 22.5 kD *Streptococcus uberis* protein or an immunogenic fragment of said protein having a length of at least 6 amino acids, said protein or immunogenic fragment thereof having an amino acid sequence homology of at least 70%, preferably 80%, more preferably 85% with the amino acid sequence as depicted in SEQ ID NO: 2 and a pharmaceutically acceptable carrier.

25 14) Vaccine for combating *Streptococcus uberis* infection, characterized in that said vaccine comprises a nucleic acid sequence according to claim 1 or 2, a DNA fragment according to claim 3, a recombinant DNA molecule according to claim 4, a live recombinant carrier according to claim 5, a host cell according to claim 6 or a protein or an immunogenic fragment thereof according to claims 7-9 and a pharmaceutically acceptable carrier.

30 15) Vaccine for combating *Streptococcus uberis* infection, characterized in that said vaccine comprises antibodies against a protein or an immunogenic fragment thereof according to claims 7-9 and a pharmaceutically acceptable carrier.

- 16) Vaccine according to claims 13-15, characterized in that said vaccine comprises an adjuvant.
- 5    17) Vaccine according to claims 13-16, characterized in that said vaccine comprises an additional antigen derived from a virus or micro-organism pathogenic to cows, an antibody against such an antigen or genetic information encoding said antigen and/or a pharmaceutical component.
- 10    18) Vaccine according to claim 17, characterized in that said virus or micro-organism pathogenic to cows is selected from the group of Bovine Herpesvirus, bovine Viral Diarrhoea virus, Parainfluenza type 3 virus, Bovine Paramyxovirus, Foot and Mouth Disease virus, *Pasteurella haemolytica*, Bovine Respiratory Syncytial Virus, *Theileria* sp., *Babesia* sp., *Trypanosoma species*, *Anaplasma* sp., *Neospora caninum*,
- 15    *Staphylococcus aureus*, *Streptococcus agalactiae*, Mycoplasma, *E. coli*, *Enterobacter*, *Klebsiella*, *Citrobacter* and *Streptococcus dysgalactiae*.
- 19) Method for the preparation of a vaccine according to claims 13-18, said method comprising the admixing of a nucleic acid sequence according to claim 1 or 2, a DNA fragment according to claim 3, a recombinant DNA molecule according to claim 4, a live recombinant carrier according to claim 5, a host cell according to claim 6, a protein according to claims 7-9 or antibodies against a protein according to claims 7-9, and a pharmaceutically acceptable carrier.
- 25    20) A diagnostic kit comprising suitable detection means and a nucleic acid sequence according to claim 1 or 2 or a primer thereof, or a protein or immunogenic fragment thereof according to claims 7-9, or antibodies that are reactive with a protein according to claims 7-9.

BglII T7-promoter  
 1 atcgagatct ctagccgg aaattaac gactcaat agggagac caacggttc  
 XbaI NcoI  
 61 cctctagaaa taattttgtt taacttaag aaggagatat accatggca gcagccatca  
 M G S S H H  
 >>..his-MCS-his..>  
 EcoRV  
 121 tcatacatcat cacagcagcg gcctgggcc gcgcggcagc catatgatat cgaattcaag  
 H H H C S S G L V P R G S H M I S N S S  
 >.....his-MCS-his.....>  
 NotI BamHI  
 KpnI NheI SpeI SacI AgeI XbaI SacII  
 181 ctgggttaccg cttagctactag tgagtcacc ggtctcgagc ggcggcgat cccaccatca  
 L V P L A L V S S P V S S G R G S H H H  
 >.....his-MCS-his.....>  
 ClaI  
 241 ccatcaccat caccatcacc attaatcgat gataagctgt caaacatgag ctgtggac  
 H H H H H H \*  
 >.....his-MCS-his.....>>

Figure 1




Figure 2




Figure 3

## SEQUENCE LISTING

<110> AKZO Nobel N.V.

<120> Novel mastitis vaccine

<130> 2002.013

<160> 2

<170> PatentIn version 3.1

<210> 1

<211> 603

<212> DNA

<213> Streptococcus uberis

<220>

<221> CDS

<222> (1) .. (600)

<223>

<400> 1

atg ttt aaa ttt tta aag cgt gtt gtt ttt cta gct ttt ctg att ttt

48

Met Phe Lys Phe Leu Lys Arg Val Val Phe Leu Ala Phe Leu Ile Phe  
1 5 10 15

tgt ttt tat caa gct tat ata aca cat caa aat gta caa aat gtc atg  
96

Cys Phe Tyr Gln Ala Tyr Ile Thr His Gln Asn Val Gln Asn Val Met  
20 25 30

caa tac aaa cca atg gtt gaa aaa acc ttg gct gaa aat gat acg act  
144

Gln Tyr Lys Pro Met Val Glu Lys Thr Leu Ala Glu Asn Asp Thr Thr  
35 40 45

gcc aat gtc aat tta gtt tta gca atg atc tac aca gaa aca aaa ggt  
192  
Ala Asn Val Asn Leu Val Leu Ala Met Ile Tyr Thr Glu Thr Lys Gly  
50 55 60

ggt cag gca gat gtc atg caa tct agc gaa agt agt agt ggt gtg act  
240  
Gly Gln Ala Asp Val Met Gln Ser Ser Glu Ser Ser Ser Gly Val Thr  
65 70 75 80

aac tca att acc gac agt caa tct agt att caa cac ggt gtc aaa ctc  
288  
Asn Ser Ile Thr Asp Ser Gln Ser Ser Ile Gln His Gly Val Lys Leu  
85 90 95

ttg tct gag aat ttg act tta gct gag aaa gct gga gta gac tct tgg  
336  
Leu Ser Glu Asn Leu Thr Leu Ala Glu Lys Ala Gly Val Asp Ser Trp  
100 105 110

act gca gta caa gct tac aat ttt gga aca gct tac att gat tat gtg  
384  
Thr Ala Val Gln Ala Tyr Asn Phe Gly Thr Ala Tyr Ile Asp Tyr Val  
115 120 125

gca aaa aat ggt ggt gac aac act atc tct ttg gct agt cat tat tct  
432  
Ala Lys Asn Gly Gly Asp Asn Thr Ile Ser Leu Ala Ser His Tyr Ser  
130 135 140

aaa agt gtt gta gct cca agt tta ggg aat aag gat gga aaa atg tat  
480  
Lys Ser Val Val Ala Pro Ser Leu Gly Asn Lys Asp Gly Lys Met Tyr  
145 150 155 160

tta tat tac cat cca att gcc ctc ctc tat ggc ggt aaa ctt tat caa  
528  
Leu Tyr Tyr His Pro Ile Ala Leu Leu Tyr Gly Gly Lys Leu Tyr Gln  
165 170 175

aat ggt ggt aat att tat tat tca cga gaa gtt cat ttt aat tat tac  
576  
Asn Gly Gly Asn Ile Tyr Tyr Ser Arg Glu Val His Phe Asn Tyr Tyr  
180 185 190

ctc ata caa tta tta tct aaa ttt taa  
603  
Leu Ile Gln Leu Leu Ser Lys Phe  
195 200

<210> 2

<211> 200

<212> PRT

<213> Streptococcus uberis

&lt;400&gt; 2

Met Phe Lys Phe Leu Lys Arg Val Val Phe Leu Ala Phe Leu Ile Phe  
1 5 10 15

Cys Phe Tyr Gln Ala Tyr Ile Thr His Gln Asn Val Gln Asn Val Met  
20 25 30

Gln Tyr Lys Pro Met Val Glu Lys Thr Leu Ala Glu Asn Asp Thr Thr  
35 40 45

Ala Asn Val Asn Leu Val Leu Ala Met Ile Tyr Thr Glu Thr Lys Gly  
50 55 60

Gly Gln Ala Asp Val Met Gln Ser Ser Glu Ser Ser Ser Gly Val Thr  
65 70 75 80

Asn Ser Ile Thr Asp Ser Gln Ser Ser Ile Gln His Gly Val Lys Leu  
85 90 95

Leu Ser Glu Asn Leu Thr Leu Ala Glu Lys Ala Gly Val Asp Ser Trp  
100 105 110

Thr Ala Val Gln Ala Tyr Asn Phe Gly Thr Ala Tyr Ile Asp Tyr Val  
115 120 125

Ala Lys Asn Gly Gly Asp Asn Thr Ile Ser Leu Ala Ser His Tyr Ser  
130 135 140

Lys Ser Val Val Ala Pro Ser Leu Gly Asn Lys Asp Gly Lys Met Tyr  
145 150 155 160

Leu Tyr Tyr His Pro Ile Ala Leu Leu Tyr Gly Gly Lys Leu Tyr Gln  
165 170 175

Asn Gly Gly Asn Ile Tyr Tyr Ser Arg Glu Val His Phe Asn Tyr Tyr  
180 185 190

Leu Ile Gln Leu Leu Ser Lys Phe  
195 200

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 03/08704

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
IPC 7 C12N15/31 C07K14/315 C12N1/21 C12N15/63		
<p>According to International Patent Classification (IPC) or to both national classification and IPC</p>		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) <b>IPC 7 C07K</b>		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the International search (name of data base and, where practical, search terms used) <b>EPO-Internal, SEQUENCE SEARCH, WPI Data, PAJ, MEDLINE, BIOSIS, EMBL, EMBASE</b>		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>WO 02 092818 A (BUCHRIESER CARMEN ;KUNST FRANK (FR); POYART CLAIRE (FR); COUVE ELI)      21 November 2002 (2002-11-21)</p> <p>page 3, line 15 -page 10, line 34      page 17, line 1 -page 19, line 19      page 37, line 21 -page 38, line 4      page 39, line 1 -page 40, line 20</p> <p>Sequence Listings: SEQ ID Nos.      0109,0214,2414,4550      claims 1-5,99-102</p> <p>---</p> <p style="text-align: center;">-/--</p>	1-4,6, 11-16, 19,20
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.
<p>* Special categories of cited documents :</p> <ul style="list-style-type: none"> <li>*A* document defining the general state of the art which is not considered to be of particular relevance</li> <li>*E* earlier document but published on or after the international filing date</li> <li>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</li> <li>*O* document referring to an oral disclosure, use, exhibition or other means</li> <li>*P* document published prior to the international filing date but later than the priority date claimed</li> </ul> <p style="margin-top: 10px;">*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p style="margin-top: 10px;">*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p style="margin-top: 10px;">*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p style="margin-top: 10px;">*&amp;* document member of the same patent family</p>		
Date of the actual completion of the international search	Date of mailing of the international search report	
20 November 2003	28/11/2003	
Name and mailing address of the ISA	Authorized officer	
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Donath, C	

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 03/08704

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EPOFETCH 'Online! 1 July 2002 (2002-07-01) Database accession no. ABN68115 XP002228319 the whole document -& DATABASE EPOFETCH 'Online! 2 July 2002 (2002-07-02) Database accession no. ABP27484 XP002228320 the whole document & WO 02 34771 A (CHIRON SPA. & INST. GENOMIC RES.) 2 May 2002 (2002-05-02)	1-4, 6-10
Y	---	5
X	DATABASE SWISS-PROT 'Online! 15 June 2002 (2002-06-15) Database accession no. Q8P120 XP002228321 the whole document -& DATABASE EMBL 'Online! 28 March 2002 (2002-03-28) Database accession no. AE010036 XP002228322 the whole document	1-3, 7-10
Y	---	4-6
X	WO 01 96379 A (UNIV SASKATCHEWAN) 20 December 2001 (2001-12-20) page 5, line 13 -page 7, line 29 page 12, line 1 -page 19, line 17; claims 1,5-7,10,14-16,20-32 Sequence Listings: SEQ ID No.18	11-20
X	WO 01 96381 A (UNIV SASKATCHEWAN) 20 December 2001 (2001-12-20) page 11, line 6 -page 17, line 18 Sequence Listings: SEQ ID No.10 claims 1.11,18,22-24,28-30,39-41	11-16, 19,20
Y	VERMEULEN A N: "PROGRESS IN RECOMBINANT VACCINE DEVELOPMENT AGAINST COCCIDIOSIS A REVIEW AND PROSPECTS INTO THE NEXT MILLENNIUM" INTERNATIONAL JOURNAL OF PARASITOLOGY, PERGAMON PRESS, GB, vol. 28, no. 7, July 1998 (1998-07), pages 1121-1130, XP001024960 ISSN: 0020-7519 cited in the application page 1127, left-hand column, paragraph 3 -page 1128, right-hand column, last paragraph	4-6
	---	-/-

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 03/08704

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>TYLER J W ET AL: "Immunization and immunotherapy for mastitis"  VETERINARY CLINICS OF NORTH AMERICA: SMALL ANIMAL PRACTICE, SAUNDERS, PHILADELPHIA, US,  vol. 9, no. 3,  1 November 1993 (1993-11-01), pages 537-549, XP002095921  ISSN: 0195-5616  page 543, line 4 -page 546, last line  ---</p>	1-10
A	<p>FONTAINE M C ET AL: "Immunisation of dairy cattle with recombinant Streptococcus uberis GapC or a chimeric CAMP antigen confers protection against heterologous bacterial challenge"  VACCINE, BUTTERWORTH SCIENTIFIC.  GUILDFORD, GB,  vol. 20, no. 17-18,  22 May 2002 (2002-05-22), pages 2278-2286,  XP004353935  ISSN: 0264-410X  the whole document  ---</p>	1-20
A	<p>LEIGH J A: "Streptococcus uberis: a permanent barrier to the control of bovine mastitis?"  VETERINARY JOURNAL (LONDON, ENGLAND: 1997)  ENGLAND MAY 1999,  vol. 157, no. 3, May 1999 (1999-05), pages 225-238, XP009020371  ISSN: 1090-0233  page 233, right-hand column, paragraph 1  -page 235, left-hand column, paragraph 3  -----</p>	11-20

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP 05/08704

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 02092818	A	21-11-2002	FR WO	2824074 A1 02092818 A2	31-10-2002 21-11-2002
WO 0196379	A	20-12-2001	WO CA EP US	0196379 A2 2411919 A1 1294771 A2 2002044928 A1	20-12-2001 20-12-2001 26-03-2003 18-04-2002
WO 0196381	A	20-12-2001	WO CA EP US US	0196381 A2 2411927 A1 1332155 A2 2003165524 A1 2003082781 A1	20-12-2001 20-12-2001 06-08-2003 04-09-2003 01-05-2003

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**